Patents by Inventor George R. Granneman

George R. Granneman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20210347874
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: December 17, 2020
    Publication date: November 11, 2021
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20200017580
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: February 25, 2019
    Publication date: January 16, 2020
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20170022271
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: October 7, 2016
    Publication date: January 26, 2017
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Use of TNFalpha Inhibitor
    Publication number: 20160376360
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: July 27, 2015
    Publication date: December 29, 2016
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Use of TNF? inhibitor
    Patent number: 9512216
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 6, 2016
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
    Patent number: 9499615
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: July 20, 2015
    Date of Patent: November 22, 2016
    Assignee: ABBVIE BIOTECHNOLOGY LTD
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING IDIOPATHIC INFLAMMATORY BOWEL DISEASE
    Publication number: 20160185849
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: July 20, 2015
    Publication date: June 30, 2016
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
    Patent number: 9187559
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: February 20, 2015
    Date of Patent: November 17, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Use of TNFalpha Inhibitor for Treatment of Psoriasis
    Publication number: 20150218268
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: April 8, 2015
    Publication date: August 6, 2015
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • USE OF TNFALPHA INHIBITOR FOR TREATMENT OF PSORIATIC ARTHRITIS
    Publication number: 20150218269
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: April 8, 2015
    Publication date: August 6, 2015
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Use of TNF? inhibitor for treatment of psoriasis
    Patent number: 9090689
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 28, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Use of TNF? inhibitor for treatment of psoriatic arthritis
    Patent number: 9085620
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 8, 2015
    Date of Patent: July 21, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Subhashis Banerjee, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • MULTIPLE-VARIABLE DOSE REGIMEN FOR TREATING TNFALPHA-RELATED DISORDERS
    Publication number: 20150175690
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: February 20, 2015
    Publication date: June 25, 2015
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Multiple-variable dose regimen for treating idiopathic inflammatory bowel disease
    Patent number: 9061005
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: March 28, 2012
    Date of Patent: June 23, 2015
    Assignee: AbbVie Biotechnology Ltd
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Use of TNF? inhibitor for treatment of psoriasis
    Patent number: 8986693
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: October 9, 2014
    Date of Patent: March 24, 2015
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Use of TNFAlpha Inhibitor for Treatment of Psoriasis
    Publication number: 20150071938
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Application
    Filed: October 9, 2014
    Publication date: March 12, 2015
    Inventors: Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Elliot K. Chartash, Philip Yan, George R. Granneman
  • Uses and Compositions for Treatment of Psoriasis
    Publication number: 20150050216
    Abstract: The invention provides methods, uses and compositions for the treatment of psoriasis. The invention describes methods and uses for treating psoriasis, wherein a TNF? inhibitor, such as a human TNF? antibody, or antigen-binding portion thereof, is used to treat psoriasis in a subject. Also described are methods for determining the efficacy of a TNF? inhibitor for treatment psoriasis in a subject.
    Type: Application
    Filed: July 8, 2014
    Publication date: February 19, 2015
    Inventors: Mary Kaye Willian, Martin M. Okun, Rebecca S. Hoffman, Yihua Gu, Lisa E. Melilli, Kenneth B. Gordon, Subhashis Banerjee, Lori K. Taylor, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Use of TNF-alpha inhibitor for treatment of psoriasis
    Patent number: 8906373
    Abstract: The invention describes methods of treating erosive polyarthritis comprising administering a TNF? antibody, or antigen-binding portion thereof. The invention also describes a method for testing the efficacy of a TNF? antibody, or antigen-binding portion thereof, for the treatment of erosive polyarthritis.
    Type: Grant
    Filed: April 30, 2014
    Date of Patent: December 9, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Subhashis Banerjee, Rebecca S. Hoffman, Mark Weinberg, Lori K. Taylor, Clive E. Spiegler, Daniel E. Tracey, Elliot K. Chartash, William T. Barchuk, Philip Yan, Anwar Murtaza, Jochen G. Salfeld, Steven A. Fischkoff, George R. Granneman
  • Multiple-variable dose regimen for treating TNF?-related disorders
    Patent number: 8889136
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Grant
    Filed: April 11, 2005
    Date of Patent: November 18, 2014
    Assignee: AbbVie Biotechnology Ltd.
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan
  • Multiple-variable dose regimen for treating TNFa-related disorders
    Publication number: 20130122011
    Abstract: Multiple-variable dose methods for treating TNF?-related disorders, including Crohn's disease and psoriasis, comprising administering TNF? inhibitors, including TNF? antibodies, are described. Multiple-variable dose methods include administration of a TNF-inhibitor in an induction or loading phase followed by administration of the agent in a maintenance or treatment phase, wherein the TNF-inhibitor is administered in a higher dosage during the induction phase.
    Type: Application
    Filed: March 28, 2012
    Publication date: May 16, 2013
    Inventors: Rebecca S. Hoffman, Elliot K. Chartash, Lori K. Taylor, George R. Granneman, Philip Yan, Susan K. Paulson, Joanna Z. Peng